NDAINHALATIONPOWDER
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Trelegy Ellipta is a triple-combination inhaled powder containing fluticasone furoate (ICS), umeclidinium bromide (LAMA), and vilanterol (LABA) for maintenance treatment of chronic obstructive pulmonary disease (COPD). It combines anti-inflammatory, bronchodilator, and long-acting beta-agonist mechanisms in a single daily dose via the Ellipta dry powder inhaler.
$4.5BPart D
PeakStable
4.4 years to LOEPeak-stage product with $4.5B annual Part D spending signals a mature, high-revenue franchise with established commercial infrastructure and stable team headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD
Started Oct 2022
463 enrolled
Pulmonary Disease, Chronic Obstructive
Why This Matters for Your Career
Worked on TRELEGY ELLIPTA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.